Asthma in pregnancy: An update

Simon Couillard1,2, Clare Connolly1, Catherine Borg1 and Ian Pavord1

Abstract
Aim: To update obstetric care providers about asthma management.
Summary: Asthma is the most frequent comorbid chronic illness in pregnancy. Convincing evidence shows that uncontrolled asthma magnifies the risk of maternal, fetal and neonate complications. Unfortunately, one in four women take no inhaler during pregnancy, and it is likely that decreased adherence, rather than changes in pathology, explains uncontrolled maternal asthma. Patient surveys reveal a need for information and reassurance.

Although some molecules are preferred in pregnancy, there is currently no basis to withhold any asthma medication – old or new. Biomarkers such as blood eosinophils and fractional exhaled nitric oxide are an effective way to assess the risk of asthma attacks and the likelihood of responding to inhaled steroids. Furthermore, practice-changing trials in mild asthma show that switching reliever-only regimens to as-needed ‘controller-and-reliever’ therapy is effective. We suggest that applying these changes can alleviate women’s concerns and improve outcomes.

Keywords
Asthma, pregnancy, biomarkers, FeNO, blood eosinophils, maternal outcomes, fetal outcomes

Date Received: 5 August 2020; accepted: 16 September 2020

Introduction
Asthma is a disorder of the airways that is characterised by typical symptoms and attacks of severe bronchoconstriction arising from a complex interplay between chronic inflammation and disordered airway function. It is the most common chronic disease in pregnancy, affecting 3–12% of women. There is now a compelling evidence that poor asthma control and asthma attacks in pregnancy are associated with adverse pregnancy outcomes. Pregnancy should therefore prompt a review of management in order to achieve control and reduce the risk of acute asthma attacks. This article aims to update obstetric care providers on the stratification and management of pregnant women with asthma.

Applied respiratory pathophysiology in pregnancy

Healthy pregnancy and the airways
Healthy pregnancy brings clinically significant changes to the respiratory system that may impact the evaluation and management of asthma (Table 1). Anatomic changes, although the most obvious manifestation of pregnancy and responsible for the changes in lung volumes noted in Table 1, have little consequence on the airways. However, the change in abdominal girth, pressure, diaphragmatic position and chest wall size contributes to the increasing incidence of physiological dyspnoea in later stages (Figure 1). Similarly, the enlarging uterus favours acid reflux. Nevertheless, there is no decrease in dynamic spirometry values.

Immune changes in pregnancy are documented, yet poorly understood and of uncertain relevance to asthma. Reduced cell-mediated immunity probably explains the higher risk for infection from seasonal and/or H1N1 pandemic influenza. In mice, successful implantation requires a locally downregulated T-helper-1 type (Th) micro-environment – in favour of Th2 – to ensure the tolerance of the ‘fetal allograft’. Conversely, in humans, there is no predominance of circulating Th2 cytokines (i.e. interleukin (IL)-4, 5 and 13) or blood eosinophils in healthy pregnancy compared to non-pregnant women. In fact, plasmatic levels of eotaxin – an important eosinophil chemokine – decrease.
To summarise, although shortness of breath, heartburn, rhinitis and viral infections can occur in normal pregnancy, lower airway pathology does not.

**Key pathological features of asthma**

The fundamental features of asthma are chronic airway inflammation, structural changes to the airways and airway hyperresponsiveness.

**Chronic airway inflammation.** The asthmatic airway inflammatory response is now acknowledged to be heterogeneous. In 40–70% of cases, it is characterised by varying degrees of airway eosinophilic infiltration orchestrated by type 2 cells, producing the key cytokines IL-4, 5 and 13. These cytokines increase production of allergen-specific immunoglobulin (Ig)E and play an important role in the maintenance of eosinophilic airway inflammation. Collectively, this response is known as type 2 airway inflammation (Figure 2).

Approximately half of women with asthma studied when stable and during an attack have no evidence of type 2 airway inflammation. This has been reported in severe asthma and in women with mild asthma who are not treated with inhaled corticosteroids (ICS), and the absence of eosinophilic airway inflammation has been confirmed by bronchoscopy studies. 'Type 2-low' asthma is associated with a lower risk of asthma attacks and a reduced response to corticosteroids.

**Structural changes to the airways.** Structural changes in airway morphology (airway remodelling) occur as a result of chronic airway inflammation and dysfunction. Key features of airway remodelling include thickening of the sub-epithelial basement membrane caused by abnormal deposition of collagen; increased airway smooth muscle bulk; increased mucus-secreting cells and increased airway vascularity. It is thought that airway remodelling underlies the progressive airflow limitation seen in some women with asthma.

**Airway hyperresponsiveness.** Airway hyperresponsiveness represents an exaggerated bronchoconstrictor response to a variety of exogenous inhaled stimuli causing bronchoconstriction either by a
direct effect on airway smooth muscle or by indirectly interacting with neural pathways or mast cells.\(^{31}\)

**Pre-conception: Asthma and (sub)fertility**

As it is frequently observed in chronic inflammatory diseases, women with asthma are more likely to be subfertile.\(^{32-35}\) Importantly, women treated with an ICS tend to have better fertility as opposed to no inhaler or short-acting beta-agonist (SABA)-only.\(^{33,35}\) There is still no high-quality prospective data to back ICS-use to optimise fertility in asthma. However, common sense and clinical experience suggest that uncontrolled and/or severe asthma hinder conception success.\(^{36}\)

**Asthma and pregnancy**

**Obstetric risk varies with asthma control.** Asthma is associated with a slight increase in maternal and fetal complications.\(^{37-47}\) Importantly, uncontrolled asthma magnifies these risks. A recent well-designed Canadian study of 103,424 singleton pregnancies in women with asthma showed that antepartum asthma attacks were associated with significantly higher rates of congenital malformations; preterm births; low birth weights; early life pneumonia and asthma; pregnancy-induced hypertension; and pre-eclampsia (Figure 3).\(^3\)

**Are the effects of pregnancy on asthma truly ‘unpredictable’?**

Pregnancy often affects the course of asthma although this is variable and relatively unpredictable. Several studies have shown that asthma severity prior to conception\(^{48,49}\) smoking,\(^{50}\) uncontrolled rhinitis\(^{12}\) and obesity\(^{51}\) are predictors of asthma attacks during pregnancy. The common wisdom that ‘one third of pregnant women experience an improvement in their asthma, one third experience a deterioration of their symptoms, and one third remain unchanged’ was confirmed by a meta-analysis of 14 studies.\(^{52}\) If symptoms do worsen, this is most likely in the second and third trimesters, with the peak incidence in month six.\(^{53}\) Peripartum and postpartum exacerbations are less frequent.\(^{40}\)

Although many hypotheses exist, the mechanisms behind the aggravation of certain cases of asthma during pregnancy remain unclear.\(^{54}\) There is no tangible proof that type 2 airway inflammation – an important driver in asthma – increases spontaneously during pregnancy. Pregnancy-related conditions, micro-aspirations and susceptibility to viral infections may play a confounding role. Unfortunately, decreased adherence to asthma controller therapy seems the major factor at play.

**The effect of pregnancy on adherence.** The major role for poor treatment adherence is supported by pharmaco-epidemiological studies showing that asthma controller pick-up rates decrease by 17–30% during the first trimester.\(^{55,56}\) Prospective in-depth interviews reveal that lack of information, concerns about the safety of the medications and the desire for a ‘natural’ pregnancy were frequent reasons for discontinuation.\(^{36,57}\) Healthcare providers need to be able to answer the questions these women have about continuing asthma therapies and their safety throughout pregnancy and breastfeeding and, ideally,
utilise strategies that ensure that the available treatments are used to their maximum potential.

**Evaluation**

**Diagnosis**

Characteristic clinical features (Table 2) coupled with objective demonstration of variable airflow obstruction (Table 3) and/or type 2 airway inflammation (Table 4) usually provide enough evidence to make the diagnosis of asthma.\(^5\) In uncomplicated pregnancies, spirometry is safe,\(^5\) but exercise and methacholine challenges are relatively contraindicated.\(^6,\)\(^5\)

**Biomarker assessment**

Biomarkers are useful surrogate measures of type 2 airway inflammation, the risk of asthma attacks and the likelihood that ICS will be effective (Table 4). An up-to-date full blood count (including eosinophils) and assessment of fractional exhaled nitric oxide (FeNO) are the most effective way of doing this. A blood eosinophil count <0.15 \(\times 10^9/\text{L}\) makes type 2 inflammation very unlikely to be present, whereas a count >0.3 \(\times 10^9/\text{L}\) makes it likely. The corresponding values for FeNO are 25 and 50 ppb. Blood eosinophils reflect IL-5 activity in the airway and systemically and FeNO IL-13 and 4 activity so these biomarkers likely have additive predictive and prognostic value. In keeping with this, type 2 inflammation and clinical outcomes associated with it are particularly likely if both biomarkers are elevated.\(^5\) There is now a convincing evidence that a treatment strategy that seeks to normalise FeNO results in better outcomes for mother and child than a symptom-guided approach.\(^6,\)\(^4\)

**Allergy testing**

Confirming atopy with skin-prick testing or measurement of total IgE and allergen-specific IgE may help support a diagnosis of atopic asthma. Positive serology must be clinically correlated. We commonly check for sensitisation to *Aspergillus fumigatus*, house-dust mites and pollen; if there are any household pets, these are included. Testing can provide an important guide to allergen avoidance strategies and pharmacological treatments such as antihistamines, intranasal corticosteroids and, in certain cases, anti-IgE treatment.

**Management of asthma in pregnancy**

**Aims**

There are three major consequences of asthma and management goals that are directed at addressing each of these:

1. Control of asthma symptoms
2. Prevention of asthma attacks
3. Preservation of normal lung function

Importantly, these clinical outcomes involve different mechanistic pathways and therefore need different treatment approaches. Non-pharmacological and pharmacological measures are both important.

**Non-pharmacological interventions**

Inadequate information, education and advice on managing asthma are key contributors to asthma exacerbations.

**Patient education.** Appropriate patient education is essential for the provision of patient-centred care. There are several aspects to this:

- Identifying and avoiding asthma triggers, most importantly smoking cessation;

**Table 2.** Clinical features that increase and decrease the probability that episodic respiratory symptoms are due to asthma.

| Features that increase the probability of asthma | Features that lower the probability of asthma |
|-------------------------------------------------|-----------------------------------------------|
| More than one of the following symptoms: cough, breathlessness, wheeze and chest tightness | Prominent dizziness, light-headedness and peripheral tingling |
| Symptoms worse at night and in the early morning | Isolated cough |
| Symptoms in response to exercise, allergen exposure and cold air | Repeatedly normal physical examination of chest when symptomatic |
| Symptoms after taking aspirin or b-blockers | Normal PEF when symptomatic |
| History of atopic disorder | Voice disturbance |
| Family history of asthma and/or atopic disorder | Symptoms with colds only |
| Variable wheeze heard on auscultation of the chest | Chronic productive cough |
| Variable PEF (see Table 3) | Significant smoking history (i.e. >20 pack-years) |
| Otherwise unexplained low PEF | Cardiac disease |

PEF: peak expiratory flow.

**Table 3.** Confirming variable expiratory airflow limitation in adults.

| Diagnostic feature | Criteria for making the diagnosis |
|--------------------|----------------------------------|
| Spirometry with reversible airflow obstruction | FEV\(_1\)/FVC ratio decreased (\(<0.75–0.80\)) \AND increase in FEV\(_1\) of \(>12\%\) and \(>200\) mL from baseline: 10 min after 400 mcg salbutamol \OR four weeks of anti-inflammatory therapy \OR between visits |
| Excessive variability in twice-daily PEF over two weeks | Average daily diurnal PEF variability > 10% |
| Positive exercise challenge\(^6\) | Fall in FEV\(_1\) > 10% and >200 mL |
| Positive bronchial challenge\(^6\) | Fall in FEV\(_1\) of 20% with methacholine concentration \(<8\) mg/mL |

\(^6\)Avoid in pregnancy, as relatively contra-indicated.

FEV\(_1\): forced expiratory volume in 1 s; FVC: forced vital capacity; PEF: peak expiratory flow.

Adapted from Global Initiative for Asthma (GINA).\(^5\)
ICSs are the mainstay of asthma pharmacotherapy.

Although experience in human pregnancy is limited, a growing body of evidence indicates the use of ICS, as indicated, during pregnancy is safe. Of particular interest is the use of beclomethasone, fluticasone propionate, and mometasone, which are the preferred molecules for pregnancy. Noteworthy are the two randomised, placebo-controlled trials supporting the efficacy and safety of beclomethasone-mometasone for oral inhalation. The former administration route certainly has a much better safety profile. ICSs reduce exposure to systemic steroids; the former administration route certainly has a much better safety profile. ICSs reduce exposure to systemic steroids; the former administration route certainly has a much better safety profile.

Bronchodilators. Bronchodilators have no measurable effects on eosinophilic airway inflammation, and their use as first-line agents in women with asthma is no longer recommended. To be clear, even in mild asthma, there is evidence of harm from SABA-only treatment.

Table 4. Biomarkers of type 2 airway inflammation.

| Biomarker                  | Cut-off          | Association with treatment response | Comments |
|----------------------------|------------------|-------------------------------------|----------|
| Allergy testing            | Variable         | Anti-IgE                             | Increases probability of atopy, but does not confirm sensitisation; IgE levels do not predict clinical outcomes under omalizumab |
| Blood eosinophil count     | ≥150–300 cells/µL | Corticosteroids                      | Generally available, cheap, associated with increased risk of asthma attacks |
| Sputum eosinophils         | ≥2–3%            | Corticosteroids Anti-IL-5 Anti-IL4Rx | Available at specialist centres, tissue specific, time-consuming |
| FeNO                       | ≥25–50 ppb       | Corticosteroids Anti-IL-5 Anti-IL4Rx | Quick, cheap, not specific; increases probability of asthma diagnosis; associated with increased risk of asthma attacks |

FeNO: fractional exhaled nitric oxide; IgE: immunoglobulin E; IL: interleukin; R: receptor.

Adapted from Pavord et al.72

- Understanding the role of different prescribed therapies (i.e. distinguishing ‘relievers’ and ‘controllers’);
- Encouraging compliance with medication and annual flu vaccination;
- Ensuring correct inhaler technique;
- Recording and monitoring peak flow;
- Following a self-management plan.

Specialist asthma nurses are central providers of information and education for women. Regular follow-up with an asthma nurse reinforces key messages and leads to superior asthma control.

Smoking cessation and allergen avoidance. Five pregnant women died from asthma in the UK between 2009 and 2015; all were current smokers.65,66 Smoking cessation improves asthma control, maternal health and fetal outcomes. Planning and reviewing pregnancy are ideal opportunities to start a cessation programme. Indeed, up to 75% of pregnant smokers successfully stop smoking by the end of pregnancy.67–70

Airborne allergen exposure and sensitisation are common and often contribute to increased asthma symptoms. Simple measures such as limiting contact with household pets, notably in the bedroom, should be counselled. Airborne and/or food allergen avoidance might be beneficial for the pregnant woman, but studies have not shown an effect on the risk of asthma in progeny.71–73

Pharmacological therapy

Pharmacological therapies are central to asthma management. National, societal and international guidelines are very clear and consistent on the point that asthma treatment does not differ in pregnant women.6,56,71 The safety and effectiveness of continuing usual inhalers and asthma medications should be reinforced as early as possible. However, when introducing a new therapy before or during pregnancy, prescribers should choose molecules with the most reassuring safety profiles.

Bronchodilators. Bronchodilators have no measurable effects on eosinophilic airway inflammation, and their use as first-line agents in women with asthma is no longer recommended. To be clear, even in mild asthma, there is evidence of harm from SABA-only treatment.78

Beta-2 agonists act by inhibiting contractility, leading to improvements in lung function and airway hyperresponsiveness. Following recent practice-changing trials in mild asthma,74–77 as-needed fast-onset long-acting β2-agonists in combination with an ICS (e.g. budesonide-formoterol or beclomethasone-formoterol) are the first step in asthma therapy. Since its authorisation for asthma in 2001, there have been no reports of teratogenic or embryocidal effects of formoterol at usual doses (<72 mcg/day). Of course, SABAs (e.g. salbutamol) can still be used to provide relief, but always in combination with a regular ICS.

Slower-onset LABAs include salmeterol, which has the longest track record of safety in pregnancy, and newer ‘ultra-long acting β2-agonists’ such as olodaterol or vilanterol. Although animal data suggest low risk for the latter two,78 these are not our first choice in pregnancy unless a once-daily LABA-ICS regimen is clearly required (e.g. fluticasone furoate and vilanterol once daily for adherence issues).

Anti-muscarinic agents cause bronchodilation by inhibiting vagal tone to the airways and have an additive effect to β2-agonists. Ipratropium is considered safe in pregnancy and is used in acute asthma attacks with minimal tachycardic effect on both mother and fetus.78 The long-acting anti-muscarinic (LAMA) tiotropium bromide has been observed to modestly decrease exacerbations in severe asthma. This class is especially useful in severe asthma with fixed airflow obstruction.79 Although experience in human pregnancy and lactation is minimal, LAMAs have been continued during pregnancy without concern.78

Corticosteroids. ICSs are the mainstay of asthma pharmacotherapy. Corticosteroids effectively suppress eosinophilic inflammation which is associated with marked improvement in symptoms, reduced exacerbation frequency and reduced asthma mortality. Response to this class of medication has been found to correlate with evidence of type 2 airway inflammation and, by extension, with blood eosinophil counts and FeNO levels. Importantly, ICSs reduce exposure to systemic steroids; the former administration route certainly has a much more reassuring safety profile than the latter.78,80–97 Budesonide, beclomethasone and fluticasone propionate are the preferred molecules for pregnancy. Noteworthy are the two randomised, placebo-controlled trials supporting the efficacy and safety of beclomethasone.93,94 There is no such data to support or to contraindicate the use of ciclesonide, mometasone or fluticasone furoate in pregnancy.

Women are often concerned about the possibility of adverse effects of ICS, and this belief is particularly prevalent in pregnant women. At low-to-moderate doses (budesonide < 800 mcg/day, beclomethasone ≤ 400 mcg/day, fluticasone propionate ≤ 500 mcg),
side effects are not significant. To minimise adverse effects, the use of spacer devices, dry powder mechanisms and mouth rinsing after inhaler use are counselled. At higher doses (less than the above doses), systemic absorption through the buccal and airway mucosa becomes increasingly important, and referral to a specialist is suggested.36

Systemic corticosteroids quickly suppress both airway and systemic eosinophilic inflammation in uncontrolled asthma.36–100 A short (five days) adequately dosed (e.g. 40 mg once daily) burst of oral prednisolone should never be withheld if clinically indicated for an acute exacerbation. Indeed, the benefits of its use greatly outweigh the potential areas of concerns this treatment raises.36,71

The risk of orofacial clefts is increased with systemic steroid use in conditions other than asthma and with maintenance doses.102 Pregnant women can be reassured that palatal closure is complete by the end of week 12, so teratogenic risk should be limited at further stages. Moreover, 90% prednisolone is metabolised by the placenta, with only 10% reaching the fetus.36,103 Finally, although preterm delivery, low birth weight and other adverse outcomes may be associated with exposure to systemic corticosteroids, one must consider confounding factors and a background rate of major birth defects in pregnancies of 2–4%.104

Anti-leukotrienes. Leukotrienes are important pro-inflammatory mediators that also promote bronchoconstriction. Cysteinyl-leukotriene receptor-1 antagonists (e.g. montelukast) have a modest suppressive effect in adults with asthma. They work best in women with exercise-induced symptoms, allergic rhinitis and/or aspirin-exacerbated respiratory disease. Although there have been worrying isolated case reports105 and low-quality retrospective publications,106 three well-designed studies have found no significant teratogenic effects.107–109 We have no qualms continuing this medication, but do not rely on montelukast to control asthma in adults and thus avoid its introduction in pregnant women.

Biologics. Biological agents (i.e. monoclonal antibodies) targeting IgE, IL-5, 4 and 13 have had a significant impact on clinical practice in severe asthma. Their exacerbation-preventing and corticosteroid-sparing effects are closely linked to easily measured biomarkers.110 Although all biological treatments are IgG-based and thus transported across the placenta in varying degrees according to gestational age and sub-type,111 there have been no concerns of teratogenicity despite being trialled and used in humans for more than two decades.

Omalizumab blocks the interaction of IgE with mast cells and basophils. IgE has an important effector role in allergic diseases, and suppression of IgE is therefore useful in the management of severe atopic asthma and/or urticaria. Clinical trials have shown fewer asthma attacks (~25% decrease compared to placebo) and greater reductions in ICS doses with no apparent adverse effects.58 Evaluated in humans since 1999112 and marketed since 2003,113 omalizumab has a long track record of safety in pregnancy. A recent analysis of an exposure registration, prospective cohort of 250 pregnant women with asthma treated with this biologic showed no increase in adverse fetal outcomes when compared to the disease-matched external cohort.92 Omalizumab is generally preferred in women desiring children.

IL-5 targeting agents directly bind IL-5 (mepolizumab and reslizumab) or indirectly block its effect by binding to its receptor (benralizumab). This strategy has proven successful in severe eosinophilic asthma where they reduce asthma attacks (~50% decrease), improve quality of life, allow withdrawal of oral corticosteroids (~50% dose decrease) and slightly improve lung function. The benefits are greater in women with a high frequency of prior asthma attacks and in those with a higher blood eosinophil count.58,114 In pregnant non-human primates (NHP), administration of mepolizumab and benralizumab surrogate-antibody doses 9 and 310-fold, the maximum recommended human dose elicited no maternal or fetal adverse effect up to nine months after birth.115,116 There is no such data for reslizumab.117 In humans, the growing clinical experience, registries and publications for these biologics – mepolizumab has been trialled in humans since 2000118 – have not provided any signal of harm in pregnancy and breastfeeding. Dupilumab inhibits IL-4 and IL-13 by binding to a common component of their receptors, the IL-4 receptor-alpha. This biological agent has a broad range of beneficial effects on asthma attack frequency (~60% decrease), quality of life, lung function and oral corticosteroid dose reduction (~50% decrease). Dupilumab is particularly attractive in women with comorbid conditions such as eczema119 and nasal polyposis120 as it is an effective treatment for both. The beneficial effects are closely related to blood eosinophil counts and FeNO levels. Experience in pregnancy is limited.121 In pregnant NHPs, doses 10 times the MRHD have been administered without any adverse outcome noted.122 In women of child-bearing age with severe uncontrolled type 2 high asthma, an appraisal of the benefit-risk ratio is key. We would rather initiate an ‘older’ biological molecule (i.e. omalizumab or mepolizumab) but have cautiously continued dupilumab in women that previously failed all other lines of therapy. Pharmacovigilance,123,124 spontaneous reporting of suspected adverse drug reactions124 and discussing registry enrolment are crucial in such cases.122

Other medications.

• Methylxanthines (e.g. theophylline or aminophylline), although poorly tolerated, are safe throughout pregnancy and breastfeeding. More frequent dose-level monitoring is necessary due to decreased metabolism and protein-binding.36

• For allergic conditions, antihistamines (e.g. cetirizine or loratadine), intranasal corticosteroids (e.g. budesonide), skin emollients and mild-to-moderate topical corticosteroid creams (e.g. hydrocortisone 0.5–2.5%) are safe throughout pregnancy and breastfeeding.110

• Initiation of subcutaneous or sublingual immunotherapy during pregnancy is not recommended due to the possibility of severe allergic reactions. Women tolerating these therapies may cautiously continue if they derive clinical benefit.125,126

Bringing it all together: State-of-the-art management of asthma in pregnancy

Guidelines recommend the titration of therapy for asthma in a step-wise manner, with the primary aim of satisfactorily controlling symptoms at the lowest dose of corticosteroid. Women with asthma should be reviewed pre-conception and more frequently until delivery. International guidelines recommend monthly assessments.58 This algorithm assumes clinical control and therefore fulfilment of all three targets of care. When there is concern that asthma control is suboptimal, consideration should be given to the changes in normal physiology – and adherence – that occur during pregnancy. Evaluation must be prompt and include objective measurements of uncontrolled asthma through spirometry and, considering recent evidence, biomarkers of type 2 airway inflammation (e.g. blood eosinophils and FeNO).

Biomarker-based management in pregnancy. In a landmark randomised-control trial of FeNO-based management of 220 non-smoking pregnant women with asthma, Powell et al.63 reported a striking reduction in moderate-to-severe exacerbations for the FeNO-and-clinical guided versus the clinical-only guided group (0.288 vs 0.615 exacerbations per pregnancy; 25 vs 41% women
with at least one exacerbation). Although the trial was not powered to assess perinatal outcomes, there were favourable trends in the progeny of FeNO-managed mothers.

In 2019, a post-hoc analysis of this trial showed that the FeNO-guided management algorithm was equally fruitful in type 2 low asthma. Indeed, 103 (53%) of the women presented with a combination of low biomarkers of type 2 airway inflammation (FeNO < 30 ppb and blood eosinophils < 260 cells/μL). In this ‘type 2-low group’, a lower median ICS dose combined with an increase in LABA therapy in the FeNO-guided arm was still associated with a decrease in exacerbations (19 vs 44% women with at least one exacerbation). Overall, treatment was better targeted to phenotype in the FeNO-guided algorithm. Earlier introduction of an LABA was observed in type 2 low asthma (11–30%) and ICS use increased in type 2 high asthma (48–86%). Biomarker-guided therapy during pregnancy is promising but will need further validation before being widely implemented.127,128

Management during labour. In labour, women with asthma should be offered the same options for pain relief as women without asthma. Prostaglandin E2 used in induction and oxytoxin used for augmentation of labour can be used as normal. Peripartum and post-partum prescriptions should include continued use of inhalers.

In obstetric bleeding, prostaglandin F2α derivatives such as carboprost should be avoided as they can cause bronchoconstriction. Women who have taken more than 7.5 mg prednisolone daily for more than two weeks should be considered for parenteral hydrocortisone.103

Conclusion
To summarise, asthma in pregnancy carries small risks yet great uncertainties for both the mother and her unborn child. We have shown compelling evidence that better control on maternal asthma favours better outcomes for both parties. Women need to be informed, reassured and empowered in their ability to control their airways disease through continued adherence to non-pharmacological and pharmacological advice. Hopefully, an up-to-date obstetric care provider can discuss newer and safer treatment regimens for their patient’s mild asthma such ICS-formoterol pro rata necessitate. In cases of uncontrolled and/or severe asthma, asthma specialists will be happy to provide advice in women appropriately diagnosed and stratified by biomarkers. A FeNO-guided algorithm enables precision medicine and results in reduced asthma attacks during pregnancy and improvements in pregnancy outcomes.

Acknowledgements
The authors thank the colleagues and patients in the Oxford University Hospitals Foundation Trust’s severe asthma clinic for help, advice and for proof reading.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethical approval
Not applicable.

Informed consent
Not applicable

Guarantor
IP is the guarantor of the present work.

Contributorship
Couillard researched the literature and drafted the manuscript. Connolly and Borg provided an early draft. Povard contributed to the early draft and reviewed and approved the manuscript. All authors reviewed and edited the manuscript and approved the final version of the manuscript.

ORCID iD
Simon Couillard https://orcid.org/0000-0002-4057-6886

References
1. Kwon HL, Belanger K and Bracken MB. Asthma prevalence among pregnant and childbearing-aged women in the United States: estimates from national health surveys. Ann Epidemiol 2003; 13: 317–324.
2. Kurinczuk JJ, Parsons DE, Dawes V, et al. The relationship between asthma and smoking during pregnancy. Women Health 1999; 29: 31–47.
3. Abdullah K, Zhu J, Gershon A, et al. Effect of asthma exacerbation during pregnancy in women with asthma: a population-based cohort study. Eur Respir J. Epub ahead of print February 2020. DOI: 10.1183/13993003.01335-2019.
4. Magriples U and Copel JA. Obstetric management of the high-risk patient. In: Burrow G, Duffy T and Copel J (eds) Medical complications during pregnancy. Philadelphia: Elsevier, 2004, p.592.
5. Gaiser R, et al. Physiologic changes of pregnancy. In: Chestnut D, Wong C and Tsen L (eds) Chestnut’s obstetric anesthesia: principles and practice. Philadelphia: Elsevier, p.1382.
6. Milne JA. The respiratory response to pregnancy. Postgrad Med J 1979; 55: 318–324.
7. Marrero JM, Goggin PM, de Caestecker JS, et al. Determinants of pregnancy heartburn. BJOG 1992; 99: 731–734.
8. Van Thiel DH, Gavalter JS and Streimple J. Lower esophageal sphincter pressure in women using sequential oral contraceptives. Gastroenterology 1976; 71: 232–234.
9. Osur SL. The management of asthma and rhinitis during pregnancy. J Womens Health (Larchmt) 2005; 14: 263–276.
10. Ellegard E, Oscarsson J, Bougoussa M, et al. Serum level of placental growth hormone is raised in pregnancy rhinitis. Arch Otolaryngol Head Neck Surg 1998; 124: 439–443.
11. Toppozada H, Michaelis L, Toppozada M, et al. The human respiratory nasal mucosa in pregnancy. An electron microscopic and histochemical study. J Laryngol Otol 1982; 96: 613–626.
12. Powell H, Murphy VE, Hensley MJ, et al. Rhinitis in pregnant women with asthma is associated with poorer asthma control and quality of life. J Asthma 2015; 52: 1023–1030.
13. Grindheim G, Torska K, Estensen M-E, et al. Changes in pulmonary function during pregnancy: a longitudinal cohort study. BIoG 2012; 119: 94–101.
14. Russell IF and Chambers WA. Closing volume in normal pregnancy. Br J Anaesth 1981; 53: 1043–1047.
15. Van Kerkhove MD, Vendamaele KAH, Shinde V, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med 2011; 8: e1001053.
Asthma and immunological diseases in pregnancy. *Am J Obstet Gynecol*. 2010; 65: 739–744.

Asthma and pregnancy. *Infectious Other Respir Virus* 2013; 7: 1033–1039.

Saito S, Nakashima A, Shima T, et al. Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. *Am J Reprod Immunol* 2010; 63: 601–610.

Mor G, Aldo P and Alvero AB. The unique immunological and microbial aspects of pregnancy. *Nat Rev Immunol* 2017; 17: 469–482.

Wegmann TG, Lin H, Guilbert L, et al. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? *Immunol Today* 1993; 14: 353–356.

Östensen M, Förger F, Nelson JL, et al. Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum. *Ann Rheum Dis* 2005; 64: 839–844.

Kraus TA, Sperling RS, Engel SM, et al. Peripheral blood cytokine profiling during pregnancy and post-partum periods. *Am J Reprod Immunol* 2010; 64: 411–426.

Broadduff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. *Am J Respir Crit Care Med* 2009; 180: 388–395.

Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. *Am J Respir Crit Care Med* 1999; 160: 1001–1008.

Peters MC, Kerr S, Dunican EM, et al. Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids. *J Allergy Clin Immunol* 2019; 143: 104–113.e14.

Mason RJ, Slutsky A, Murray JF, et al. Murray and Nadel's textbook of respiratory medicine. Amsterdam, The Netherlands: Elsevier, 2016.

Berry M, Morgan A, Shaw DE, et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. *Thorax* 2007; 62: 1043–1049.

McGrath KW, Icitovic N, Boushey HA, et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. *Am J Respir Crit Care Med* 2012; 185: 612–619.

Pavord ID, Brightling CE, Woltmann G, et al. Non-eosinophilic corticosteroid unresponsive asthma. *Lancet (London, England)* 1999; 353: 2213–2214.

Fahy JV. Type 2 inflammation in asthma-present in most, absent in many. *Nat Rev Immunol* 2015; 15: 57–65.

Gade EJ, Thomsen SF, Lindenberg S, et al. Fertility outcomes in asthma: a clinical study of 245 women with unexplained infertility. *Eur Respir J* 2016; 47: 1144–1151.

Gade EJ, Thomsen SF, Lindenberg S, et al. Asthma affects time to pregnancy and fertility; a register-based twin study. *Eur Respir J* 2014; 43: 1077–1085.

Tata LI, Hubbard RR, McKeever TM, et al. Fertility rates in women with asthma, eczema, and hay fever: a general population-based cohort study. *Am J Epidemiol* 2007; 165: 1023–1030.

Grzeskowiak LE, Smithers LG, Grierer JA, et al. Asthma treatment impacts time to pregnancy: evidence from the international SCOPE study. *Eur Respir J* 2018; 51: 1702035.
56. Enriquez R, Wu P, Griffin MR, et al. Cessation of asthma medication in early pregnancy. *Am J Obstet Gynecol* 2006; 195: 149–153.

57. Lim AS, Stewart K, Abramson MJ, et al. Asthma during pregnancy: the experiences, concerns and views of pregnant women with asthma. *J Asthma* 2012; 49: 474–479.

58. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention (2020 update), https://ginasthma.org/ (2020).

59. Graham BL, Steenbruggen I, Miller MR, et al. Standardization of Spirometry 2019 update. An Official American Thoracic Society and European Respiratory Society technical statement. *Am J Respir Crit Care Med* 2019; 200: e70–e88.

60. Coates AL, Wanger J, Cockcroft DW, et al. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. *Eur Respir J*. Epub ahead of print May 2017. DOI: 10.1183/13993003.01526-2016.

61. Radtke T, Crook S, Kaltakas G, et al. ERS statement on standardisation of cardiopulmonary exercise testing in chronic lung diseases. *Eur Respir Rev*. Epub ahead of print December 2019. DOI: 10.1183/16000617.01012-2018.

62. Pavord ID, Beasley R, Agusti A, et al. After asthma: redefining airways diseases. *Lancet* 2018; 391: 350–400.

63. Powell H, Murphy VE, Taylor DR, et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. *Lancet* 2011; 378: 983–990.

64. Murphy VE, Porsbjerg CM, Robijn AL, et al. Biomarker-guided management reduces exacerbations in non-cosinophilic asthma in pregnancy: a secondary analysis of a randomized controlled trial. *Respirology*. Epub ahead of print 26 October 2019. DOI: 10.1111/rsp.13713.

65. Knight M, Kenyon S, Brocklehurst P, et al. on behalf of MBRACE-UK. Saving lives, improving mothers’ care - lessons learned to inform future maternity care from the UK and Ireland confidential enquiries into maternal deaths and morbidity 2009–12, Oxford, 2014.

66. Shakespeare J, Tuffnell D, Kurinczuk J, et al. on behalf of MBRACE-UK. Saving lives, improving mothers’ care – lessons learned to inform maternity care from the UK and Ireland confidential enquiries into maternal deaths and morbidity 2013–15, Oxford, 2017.

67. Tong VT, Dietz PM, Morrow B, et al. Trends in smoking before, during, and after pregnancy – pregnancy risk assessment monitoring system, United States, 40 sites, 2000–2010, www.cdc.gov/mmwr/preview/mmwrhtml/ss6206a1.htm (2013, accessed 5 July 2020).

68. Tong VT, Dietz PM, Farr SL, et al. Estimates of smoking before and during pregnancy, and smoking cessation during pregnancy: comparing two population-based data sources. *Public Health Rep* 2013; 128: 179–188.

69. Curtin SC and Mathews TJ. Smoking prevalence and cessation before and during pregnancy: data from the birth certificate. *Natl Vital Stat Rep* 2014; 65: 1–13.

70. Alves E, Azevedo A, Correia S, et al. Long-term maintenance of smoking cessation in pregnancy: an analysis of the birth cohort generation XXI. *Nicotine Tob Res* 2013; 15: 1598–1607.

71. SIGN-BTS. SIGN 158. British guideline on the management of asthma, www.sign.ac.uk/sign-158-british-guideline-on-the-management-of-asthma (2019).

72. Woodcock A, Lowe LA, Murray CS, et al. Early life environmental control: effect on symptoms, sensitization, and lung function at age 3 years. *Am J Respir Crit Care Med* 2004; 170: 433–439.

73. Muraro A, Dreborg S, Hallen S, et al. Dietary prevention of allergic diseases in infants and small children. Part III: critical review of published peer-reviewed observational and interventional studies and final recommendations. *Pediatr Allergy Immunol* 2004; 15: 291–307.

74. Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. *N Engl J Med* 2019; 380: 2020–2030.

75. Hardy J, Baggott C, Fingleton J, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. *Lancet (London, England)* 2019; 394: 919–928.

76. O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. *N Engl J Med* 2018; 378: 1865–1876.

77. Bateman ED, Reddel HK, O’Byrne PM, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. *N Engl J Med* 2018; 378: 1877–1887.

78. Weinberger SE, Schatz M, and Management of asthma during pregnancy. *UpToDate*, https://www.uptodate.com/contents/management-of-asthma-during-pregnancy (2020, accessed 16 June 2020).

79. Kerstjens HAM, Engl M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. *N Engl J Med* 2012; 367: 1198–1207.

80. Van Zutphen AR, Bell EM, Browne ML, et al. Maternal asthma medication use during pregnancy and risk of congenital heart defects. *Birth Defects Res Part A Clin Mol Teratol* 2015; 103: 951–961.

81. Dombrowski MP, Brown CL and Berry SM. Preliminary experience with triamcinolone acetonide during pregnancy. *J Matern Fetal Med* 1996; 5: 310–313.

82. Dombrowski M, Thom E and McNellis D. Maternal-fetal medicine units (MFMU) studies of inhaled corticosteroids during pregnancy. *J Allergy Clin Immunol* 1999; 103: S156–S359.

83. Dombrowski MP, Schatz M, Wise R, et al. Randomized trial of inhaled beclomethasone dipropionate versus theophylline for moderate asthma during pregnancy. *Am J Obstet Gynecol* 2004; 190: 737–744.

84. Blais L, Beauchesne MF, Rey É, et al. Use of inhaled corticosteroids during the first trimester of pregnancy and the risk of congenital malformations among women with asthma. *Thorax* 2007; 62: 320–328.

85. Blais L, Beauchesne MF, Lemière C, et al. High doses of inhaled corticosteroids during the first trimester of pregnancy and congenital malformations. *J Allergy Clin Immunol* 2009; 124: 1229–1234.e4.

86. Breton MC, Beauchesne MF, Lemire C, et al. Risk of perinatal mortality associated with inhaled corticosteroid use for the treatment of asthma during pregnancy. *J Allergy Clin Immunol* 2010; 126: 772–777.e2.

87. Hodyl NA, Stark MJ, Osei-Kumah A, et al. Fetal glucocorticoid-regulated pathways are not affected by inhaled corticosteroids during formation of asthma. *Am J Respir Crit Care Med* 2011; 183: 716–722.

88. Tegethoff M, Greene N, Olsen J, et al. Inhaled glucocorticoids during pregnancy and offspring pediatric diseases: a national cohort study. *Am J Respir Crit Care Med* 2012; 185: 557–563.

89. Wendel PJ, Ramin SM, Barnett-Hamm C, et al. Asthma treatment in pregnancy: a randomized controlled study. *Am J Obstet Gynecol* 1996; 175: 150–154.
90. Källén B, Rydhstroem H and Aberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. *Obstet Gynecol* 1999; 93: 392–395.
91. Schatz M, Dombrowski MP, Wise R, et al. The relationship of asthma medication use to perinatal outcomes. *J Allergy Clin Immunol* 2004; 113: 1040–1045.
92. Namazy J, Schatz M, Long L, et al. Use of inhaled steroids by pregnant asthmatic women does not reduce intrauterine growth. *J Allergy Clin Immunol* 2004; 113: 427–432.
93. Lim A, Stewart K, König K, et al. Systematic review of the safety of regular preventive asthma medications during pregnancy. *Ann Pharmacother* 2011; 45: 931–945.
94. Bakhireva LN, Jones KL, Schatz M, et al. Asthma medication use in pregnancy and fetal growth. *J Allergy Clin Immunol* 2005; 116: 503–509.
95. Martel M-J, Rey E, Beauchesne M-F, et al. Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study. *BMJ* 2005; 330: 230.
96. Norjavaira E and de Verdier MG. Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonide. *J Allergy Clin Immunol* 2003; 111: 736–742.
97. Greenberger PA and Patterson R. Beclomethasone dipropionate for severe asthma during pregnancy. *Ann Intern Med* 1983; 98: 478–480.
98. Belda J, Margarit G, Martínez C, et al. Anti-inflammatory effects of high-dose inhaled fluticasone versus oral prednisone in asthma exacerbations. *Eur Respir J* 2007; 30: 1143–1149.
99. Pizzichini MM, Pizzichini E, Clelland L, et al. Sputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatment. *Am J Respir Crit Care Med* 1997; 155: 1501–1508.
100. Thorn GW, Renold AE, Wilson DL, et al. Clinical studies on the activity of orally administered cortisone. *N Engl J Med* 1951; 245: 549–555.
101. Moran AM, Ramakrishnan S, Berg CA, et al. Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma. *Am J Respir Crit Care Med* 2013; 188: 119: 618–625.
102. UKTIS. Use of systemic corticosteroids in pregnancy. *Monograph, www.medicinesinpregnancy.org/bumps/monographs/USE-OF-CORTICOSTEROIDS-IN-PREGNANCY/ (2016, accessed 5 July 2020).
103. Girling J. Prescribing for pregnancy: asthma. *Drug Ther Bull* 2020; 58: 41–44.
104. Bacino CA. Birth defects: epidemiology, types and patterns. *UpToDate, www.uptodate.com/contents/birth-defects-epidemiology-types-and-patterns (2020, accessed 5 July 2020).
105. Heinonen OP, Spile L and Shapiro S. Birth defects and drugs in pregnancy. Littleton: Publishing Sciences Group, 1977.
106. Källén B and Otterblad Olausson P. Use of anti-asthmatic drugs during pregnancy. III. Congenital malformations in the infants. *Eur J Clin Pharmacol* 2007; 63: 383–388.
107. Sarkar M, Koren G, Kalra S, et al. Montelukast use during pregnancy: a multicentric, prospective, comparative study of infant outcomes. *Eur J Clin Pharmacol* 2009; 65: 1259–1264.
108. Bakhireva LN, Jones KL, Schatz M, et al. Safety of leukotriene receptor antagonists in pregnancy. *J Allergy Clin Immunol* 2007; 119: 618–625.
109. Cavero-Carbonell C, Vinkel-Hansen A, Rabanque-Hernández MJ, et al. Fetal exposure to montelukast and congenital anomalies: a population based study in Denmark. *Birth Defects Res B 2017; 109: 452–459.
110. Peters MC and Wenzel SE. Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma. *Lancet* 2020; 395: 371–383.
111. Palmeira P, Quinello C, Silveira-Lessa AL, et al. IgG placental transfer in healthy and pathological pregnancies. *Clin Dev Immunol*. Epub ahead of print 1 October 2011. DOI: 10.1155/2012/985646.
112. Shields RL, Whether WR, Zionscheck K, et al. Inhibition of allergic reactions with antibodies to IgE. *Int Arch Allergy Immunol* 1995; 107: 308–312.
113. US Food and Drug Administration (FDA). Highlights of prescribing information: Xolair® (omalizumab), 2016.
114. Pavord ID, Shrimanker R and Hanania NA. Biologics targeting type 2 inflammation in severe asthma. *Sev Asthma* 2019; 285: 303.
115. US Food and Drug Administration (FDA). Highlights of prescribing information: Nucala® (mepolizumab), 2015.
116. US Food and Drug Administration (FDA). Highlights of prescribing information: Fasenra® (benralizumab), 2017.
117. US Food and Drug Administration (FDA). Highlights of prescribing information: Cinquair® (reslizumab), 2016.
118. Leckie MJ, Ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. *Lancet* 2000; 356: 2144–2148.
119. Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. *J Eur Acad Dermatol Venereol* 2019; 33: 1644–1659.
120. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. *Lancet* 2019; 394: 1638–1650.
121. Kage P, Simon JC and Treudler R. A case of atopic eczema treated safely with dupilumab during pregnancy and lactation. *J Eur Acad Dermatol Venereol* 2020; 34: e256–e257.
122. US Food and Drug Administration (FDA). Highlights of prescribing information: Dupixent® (dupilumab), 2019.
123. Publications Québec *Code of ethics of physicians*. Québec, http://legisquebec.gouv.qc.ca/en/ShowDoc/cr/M-9, r. 17 (2020, accessed 11 August 2020).
124. Schatz SN and Weber RJ. Adverse drug reactions. In: *Pharmacotherapy self-assessment program*. Ashburn, VA: American College of Clinical Pharmacy. Epub ahead of print 2015. DOI: 10.1016/j.mpac.2020.01.011.
125. Greenhawt M, Oppenheimer J, Nelson M, et al. Sublingual immunotherapy: a focused allergen immunotherapy practice parameter update. *Ann Allergy, Asthma Immunol* 2017; 118: 276–282.e2.
126. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. *J Allergy Clin Immunol* 2011; 127: S1–S55.
127. Brightling CE. Asthma exacerbations during pregnancy: a need for precision medicine. *Respirology*. Epub ahead of print 16 December 2019. DOI: 10.1111/res.13761.
128. Bain E, Pierides KL, Clifton VL, et al. Interventions for managing asthma in pregnancy. *Cochr Database Syst Rev*. Epub ahead of print 21 October 2014. DOI: 10.1002/14651858.CD010660.pub2.